Dr. Behfar Ehdaie

I think the discomfort was still uncomfortable. Of course, we transitioned to transperineal biopsies in clinic now, which are its own challenge. But the point is, we were able to run a trial again, low cost, greater cruel. And remember, when you talk about a cruel, I don't think of just about a cruel for a trial. I think of it as from the perspective of access.

I think the discomfort was still uncomfortable. Of course, we transitioned to transperineal biopsies in clinic now, which are its own challenge. But the point is, we were able to run a trial again, low cost, greater cruel. And remember, when you talk about a cruel, I don't think of just about a cruel for a trial. I think of it as from the perspective of access.

Now, almost 80% of our patients who are getting biopsies at Memorial Sloan Kettering had access to a trial as opposed to, oh, I forgot to tell this patient about our trial. I was a busy day in clinic. I was running behind, so I couldn't really talk about this. Or, oh, our fellow didn't discuss this with the patient.

Now, almost 80% of our patients who are getting biopsies at Memorial Sloan Kettering had access to a trial as opposed to, oh, I forgot to tell this patient about our trial. I was a busy day in clinic. I was running behind, so I couldn't really talk about this. Or, oh, our fellow didn't discuss this with the patient.

Now, almost 80% of our patients who are getting biopsies at Memorial Sloan Kettering had access to a trial as opposed to, oh, I forgot to tell this patient about our trial. I was a busy day in clinic. I was running behind, so I couldn't really talk about this. Or, oh, our fellow didn't discuss this with the patient.

Every patient was being approached as a standard act by our research team all under this umbrella protocol. So it took away the human factor that I think impacts access. And of course, by decluttering the initial consent, patients felt autonomy. They had better information. They felt in control.

Every patient was being approached as a standard act by our research team all under this umbrella protocol. So it took away the human factor that I think impacts access. And of course, by decluttering the initial consent, patients felt autonomy. They had better information. They felt in control.

Every patient was being approached as a standard act by our research team all under this umbrella protocol. So it took away the human factor that I think impacts access. And of course, by decluttering the initial consent, patients felt autonomy. They had better information. They felt in control.

And they understood at a very basic level what we were doing and what was happening to them, which not surprisingly improved accrual because those patients would say, yeah, I think I want to be, I understand what's going on and I want to be part of this trial.

And they understood at a very basic level what we were doing and what was happening to them, which not surprisingly improved accrual because those patients would say, yeah, I think I want to be, I understand what's going on and I want to be part of this trial.

And they understood at a very basic level what we were doing and what was happening to them, which not surprisingly improved accrual because those patients would say, yeah, I think I want to be, I understand what's going on and I want to be part of this trial.

The patients who chose not to be part of that trial would probably not choose in any other form because they didn't want any of their outcome measures being recorded as part of any data collection. So that was very separate and that was a very, very small group of patients.

The patients who chose not to be part of that trial would probably not choose in any other form because they didn't want any of their outcome measures being recorded as part of any data collection. So that was very separate and that was a very, very small group of patients.

The patients who chose not to be part of that trial would probably not choose in any other form because they didn't want any of their outcome measures being recorded as part of any data collection. So that was very separate and that was a very, very small group of patients.

So, I think some of the other pitfalls that you learn most about was you have to make sure you meet with your clinical research team bimonthly. So every two weeks, even if you've only enrolled one patient in any trial, it is worthwhile to get everyone in a room, or nowadays on Zoom,

So, I think some of the other pitfalls that you learn most about was you have to make sure you meet with your clinical research team bimonthly. So every two weeks, even if you've only enrolled one patient in any trial, it is worthwhile to get everyone in a room, or nowadays on Zoom,

So, I think some of the other pitfalls that you learn most about was you have to make sure you meet with your clinical research team bimonthly. So every two weeks, even if you've only enrolled one patient in any trial, it is worthwhile to get everyone in a room, or nowadays on Zoom,

And have a conversation because A, there's a lot of blind spots you may not be aware of that your research study assistants are aware of. Or if there's a medical student working with you or a resident or fellow. B, it keeps people engaged because there's an update that needs to be provided every two weeks.

And have a conversation because A, there's a lot of blind spots you may not be aware of that your research study assistants are aware of. Or if there's a medical student working with you or a resident or fellow. B, it keeps people engaged because there's an update that needs to be provided every two weeks.

And have a conversation because A, there's a lot of blind spots you may not be aware of that your research study assistants are aware of. Or if there's a medical student working with you or a resident or fellow. B, it keeps people engaged because there's an update that needs to be provided every two weeks.